Меню
Идёт набор NCT03662178

Investigating the Structured Use of Ultrasound Scanning for Fetal Growth

Наблюдательное Stillbirth Fetal Death Fetal Growth Retardation Small for Gestational Age

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Stillbirth, Fetal Death, Fetal Growth Retardation, Small for Gestational Age. Базовые параметры: 16 лет — 60 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Великобритания
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Investigating the Structured Use of Ultrasound Scanning for Fetal Growth (Oxford Growth Restriction Identification Programme (OxGRIP)) on Risk Factors for and the Incidences of Adverse Maternal, Fetal and Neonatal Outcome

Обзор

Fetal growth restriction during pregnancy represents one of the biggest risk factors for stillbirth (Gardosi et al, 2013), with 'about one in three term, normally formed antepartum stillbirths are related to abnormalities of fetal growth' (MBRRACE, 2015). Therefore, antenatal detection of growth restricted babies is vital in order to be able to monitor and decide the appropriate delivery timing. However, antenatal detection of SGA babies has been poor, varying greatly across trusts in England in those that calculate their rates (NHS England, 2016). Most trusts do not calculate their detection rates and rates are therefore unknown. It is estimated that routine NHS care detects only 1 in 4 growth restricted babies (Smith, 2015). Oxford University Hospitals NHS Foundation Trust, in partnership with the Oxford Academic Health Science Network (AHSN) has introduced a clinical care pathway (the Oxford Growth Restriction Pathway (OxGRIP)) designed to increase the rates of detection of these at risk babies. The pathway is intended to increase the identification of babies who are at risk of stillbirth, in order to try to prevent this outcome, whilst making best usage of resources, and restricting inequitable practice and unnecessary obstetric intervention. It has been developed with reference to a body of research, however, the individual parts of care provided have not been put together in a pathway in this manner before. Therefore it is important to examine whether the pathway meets its goals of improving outcomes for babies in a 'real world' setting. The principles of the pathway are 1. A universal routine scan at 36 weeks gestation. 2. Additional growth scans at 28 and 32 weeks gestation based on a simplified assessment of risk factors and universal uterine artery Doppler at 20 weeks gestation. 3. Assessment of further parameters other than estimated fetal weight associated with adverse perinatal outcome (eg growth velocity, umbilical artery Doppler and CPR). The clinical data routinely collected as a result of the introduction of the pathway offers a valuable and unique resource in identifying and analysing in the effects of the pathway on its intended outcomes and also in investigating and analysing other maternal, fetal and neonatal complications and outcomes, establishing normal / reference ranges for ultrasound values.

Подробное описание

There is no requirement for patient participation in this study. All data collected and analysed is routinely collected clinical data.

Первичные конечные точки

  • Impact of OxGRIP on Perinatal mortality according to gestation [Срок оценки: 4 yrs]
Вторичные конечные точки (12)
  • Impact of the OxGRIP Pathway on service: number of scans [Срок оценки: 6 yrs]
  • Impact of the OxGRIP Pathway on service - Consultant time [Срок оценки: 6 yrs]
  • Impact of the OxGRIP Pathway on service - intrapartum interventions [Срок оценки: 6 yrs]
  • Risk Factors for adverse outcomes - ultrasound head circumference [Срок оценки: 4 yrs]
  • Risk Factors for adverse outcomes - ultrasound abdomen circumference [Срок оценки: 4 yrs]
  • Risk Factors for adverse outcomes - ultrasound femur length [Срок оценки: 4 yrs]
  • Risk Factors for adverse outcomes - ultrasound presentation [Срок оценки: 4 yrs]
  • Risk Factors for adverse outcomes - Doppler ultrasound [Срок оценки: 4 yrs]
  • Clinical outcomes during pregnancy and postnatal/neonatal period: hypertension [Срок оценки: 4 yrs]
  • Clinical outcomes during pregnancy and postnatal/neonatal period: diabetes [Срок оценки: 4 yrs]
  • Clinical outcomes during pregnancy and postnatal/neonatal period: mode of birth [Срок оценки: 4 yrs]
  • Clinical outcomes during pregnancy and postnatal/neonatal period: preterm birth [Срок оценки: 4 yrs]

Критерии участия

Критерии включения

  • All pregnant women receiving antenatal care at the Oxford University Hospitals NHS Foundation Trust (OUHFT) from January 2013 to 31st December 2019 with no exclusion criteria

Критерии исключения

  • Women who have opted out of research related to pregnancy in this pregnancy whilst receiving care by the OUHFT.
  • If intrapartum care takes place outside of the OUHFT.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Великобритания · 1 центр
  • Oxford University Hospitals NHS Foundation Trust — Oxford

Публикации

  • Chauhan SP, Magann EF. Screening for fetal growth restriction. Clin Obstet Gynecol. 2006 Jun;49(2):284-94. doi: 10.1097/00003081-200606000-00010. PMID 16721107
  • Gardosi J, Francis A. Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based percentiles. Am J Obstet Gynecol. 2009 Jul;201(1):28.e1-8. doi: 10.1016/j.ajog.2009.04.034. PMID 19576372
  • Sovio U, White IR, Dacey A, Pasupathy D, Smith GCS. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet. 2015 Nov 21;386(10008):2089-2097. doi: 10.1016/S0140-6736(15)00131-2. Epub 2015 Sep 7. PMID 26360240
  • Stacey T, Thompson JM, Mitchell EA, Zuccollo JM, Ekeroma AJ, McCowan LM. Antenatal care, identification of suboptimal fetal growth and risk of late stillbirth: findings from the Auckland Stillbirth Study. Aust N Z J Obstet Gynaecol. 2012 Jun;52(3):242-7. doi: 10.1111/j.1479-828X.2011.01406.x. Epub 2012 Jan 25. PMID 22276935
  • Papageorghiou AT, Kennedy SH, Salomon LJ, Ohuma EO, Cheikh Ismail L, Barros FC, Lambert A, Carvalho M, Jaffer YA, Bertino E, Gravett MG, Altman DG, Purwar M, Noble JA, Pang R, Victora CG, Bhutta ZA, Villar J; International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st). International standards for early fetal size and pregnancy dating based on ultrasound measurement of PMID 25044000
  • Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal risk factors for stillbirth: population based study. BMJ. 2013 Jan 24;346:f108. doi: 10.1136/bmj.f108. PMID 23349424

Идентификаторы

NCT: NCT03662178 · 17/SC/0374

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗